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 Abstract  
 
The amelogenins comprise 90% of the developing extracellular enamel matrix proteins and 
play a major role in the biomineralization and structural organization of enamel. 
Amelogenins were also detected, in smaller amounts, in postnatal calcifying mesenchymal 
tissues, and in several non-mineralizing tissues including brain. Low molecular mass 
amelogenin isoforms were suggested to have signaling activity; to produce ectopically 
chondrogenic and osteogenic-like tissue and to affect mouse tooth germ differentiation in 
vitro. Recently, some amelogenin isoforms were found to bind to the cell surface receptors; 
LAMP-1, LAMP-2 and CD63, and subsequently localize to the perinuclear region of the cell. 
The recombinant amelogenin protein (rHAM+) alone brought about regeneration of the tooth 
supporting tissues: cementum, periodontal ligament and alveolar bone, in the dog model, 
through recruitment of progenitor cells and mesenchymal stem cells.  
We show that amelogenin is expressed in various tissues of the developing mouse embryonic 
craniofacial complex such as brain, eye, ganglia, peripheral nerve trunks, cartilage and bone, 
and is already expressed at E10.5 in the brain and eye, long before the initiation of tooth 
formation. Amelogenin protein expression was detected in the tooth germ (dental lamina) 
already at E13.5, much earlier than previously reported (E19). Application of amelogenin 
(rHAM+) beads together with DiI, on E13.5 and E14.5 embryonic mandibular mesenchyme 
and on embryonic tooth germ, revealed recruitment of mesenchymal cells. The present 
results indicate that amelogenin has an important role in many tissues of the cranio-facial 
complex during mouse embryonic development and differentiation, and might be a 
multifunctional protein.  
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Introduction 
 
The amelogenins, which comprise about 90% of the enamel matrix proteins  
(Termine et al., 1980), play a major role in the biomineralization and structural 
organization of enamel ( Robinson et al., 1988;  Fincham et al., 1994). Amelogenins 
are hydrophobic molecules that self-assemble in vitro and in vivo into nanospheric 
structures which regulate the oriented and elongated growth, shape and size of the 
enamel mineral crystal (Fincham et al., 1994; Du et al., 2005). During enamel 
development and mineralization, the amelogenins in the extracellular enamel are 
sequentially and discretely degraded by specific proteases the metalloprotease 
Enamelysin (MMP20)  and the serine protease KLK4 (Simmer and Hu, 2002). The 
amelogenins are eventually, together with other enamel matrix proteins, replaced by 
mineral ions calcium and phosphorus, the enamel finally becoming hard, fully 
mineralized (96%) and mature ( Termine et al., 1980; Deutsch et al., 1995; Robinson 
et al., 1998). 
The mouse amelogenin gene is mapped to the X chromosome ( Lau et al., 
1989; Fincham et al., 1991), while in the human it maps to Xp22.1-p22.3 and Yp11.2 
chromosomes (Lau et al., 1989; Salido et al., 1992). The gene contains 9 exons ( Li et 
al., 1998; Baba et al., 2002) which undergo extensive alternative mRNA splicing 
(Simmer and Fincham, 1995; Veis, 2003; Papagerakis et al., 2005). The most 
abundant amelogenin isoform in the mouse enamel is M180, which is encoded by 
exons 1-7, skipping exon 4.  
In human, mutations in the X-chromosomal copy of the amelogenin gene 
AMELX have been associated with the hereditary disease Amelogenesis Imperfecta 
(Hart et al., 2000). Defective enamel formation has also been demonstrated by knock-
down of amelogenin expression using antisense oligonucleotides (Diekwisch et al., 
1993), ribozymes (Lyngstadaas et al., 1995) and in amelogenin knock-out and 
transgenic mice, which resulted in enamel characteristic of hypoplastic amelogenesis 
imperfecta, with reduced enamel thickness (Gibson et al., 2001). 
For decades amelogenin was thought to be exclusively an enamel (epithelial 
origin) protein. However, in more recent years different isoforms of amelogenin have 
also been found in the dentin matrix (Hammarstrom et al., 1997; Nebgen et al., 1999) 
and the odontoblasts (Oida et al., 2002; Papagerakis et al., 2003), during 
cementogenesis in remnants of Hertwig's root sheath and in periodontal ligament 
(PDL) cells (Fong and Hammarstrom, 2000; Janones et al., 2005).Very recently, we 
have described amelogenin expression in long bone cells; osteocytes, osteoblasts and 
osteoclasts, and some of the bone marrow cells. Amelogenin is also expressed in 
chondrocytes of the articular cartilage and differentially in cell layers of the 
epiphyseal growth plate. We have identified amelogenin expression in long bone 
marrow cells, some of which are mesenchymal stem cells, and in cells surrounding 
blood vessels (Haze et al., 2007). Amelogenin expression was also identified in cells 
of non-mineralizing tissues such as the brain, specifically in the glial cells, in salivary 
glands and in some of the hematopoietic cells such as megakaryocytes and 
macrophage (Deutsch et al., 2006; Haze et al., 2007). The relatively large number of 
amelogenin alternatively spliced mRNA translated polypeptides and the fact that 
amelogenin is expressed in different tissues (calcifying and soft tissues) and of 
different embryonic origin, possibly reflect different functions of amelogenin. 
Low molecular mass amelogenin isoforms were suggested to be signal 
molecules; were shown to produce ectopically chondrogenic and osteogenic-like 
tissue and to have different signaling effects on ameloblasts and odontoblasts 
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differentiation in developing tooth culture model, and when implanted in the tooth 
pulp ( Nebgen et al., 1999; Veis, 2003; Lacerda-Pinheiro et al., 2006a; Lacerda-
Pinheiro et al., 2006b; 
Zeichner-David et al., 2006; Jegat et al., 2007). Amelogenin (M180), the 
amelogenin isoform LRAP (leucin-rich amelogenin peptide), and some of the 
amelogenin degradation products, were found to bind to the cell surface receptors; 
LAMP-1, LAMP-2 and CD63, which are ubiquitously expressed lysosomal integral 
membrane proteins that are also localized to the plasma membrane. Shapiro et al. 
found that exogenously added amelogenin moves rapidly into established LAMP-1 
positive vesicles that subsequently localize to the perinuclear region of the cell 
(Shapiro et al., 2007). Zou and colleagues reported the exact regions and sequences 
that bind amelogenin to these receptors (Zou et al., 2007).  
 
A major discovery that highlights a new role for enamel matrix proteins was 
the finding that the application of an enamel matrix protein extract to tooth root 
surfaces in sites of diseased periodontium promotes the regeneration of all the 
periodontal tissues (Hammarstrom et al., 1997). It was therefore suggested that 
amelogenin is responsible for this regeneration. Recently, we showed that the 
recombinant human amelogenin protein (rHAM+), produced in the eukaryotic 
baculovirus system (Taylor et al., 2006), causes significant and progressive 
regeneration of all three tooth supporting tissues; alveolar bone, periodontal ligament 
(PDL) and cementum, after induction of chronic periodontitis, in the dog. Further 
immunohistochemistry studies, using markers for mesenchymal stem cells, combined 
with the above findings, suggested that amelogenin induces, directly or indirectly, 
recruitment of mesenchymal stem cells and/or progenitor cells, during the regeneration 
of the tooth supporting tissues (Deutsch et al., 2006). 
 
Large amount of information is available in the literature on genes and their 
corresponding proteins, associated with embryonic tooth development, 
morphogenesis and differentiation, such as signaling molecules, growth factors, 
homeoboxes etc. ( Tucker and Sharpe, 1999; Jernvall and Thesleff, 2000; Tucker and 
Sharpe, 2004; Hu et al., 2006; Mitsiadis and Smith, 2006). The same is true for all 
other craniofacial organs. However, almost no data is available on amelogenin 
expression and function in the early stages of embryonic craniofacial development.  
 
In this study we focused on the spatio-temporal expression of amelogenin in 
different tissues of the developing embryonic mouse craniofacial complex, such as 
the tooth germ, brain, eye, ganglia, peripheral nerve trunks, cartilage and bone. Our 
results indicate that amelogenin is expressed in many tissues of the cranio-facial 
complex during mouse embryonic development and differentiation, pointing to the 
possibility that it might be a multifunctional protein.  
 
 
Results 
 
Amelogenin mRNA expression in the craniofacial complex during mouse 
embryonic days E10.5–E17.5. 
The expression of amelogenin mRNA, in the craniofacial complex at E10.5 up 
to E17.5, was analyzed by RT-PCR, followed by cDNA sequencing (Fig. 1A). The 
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most abundant amelogenin isoform in the extracellular enamel matrix, M180 (exons 
1-7 lacking exon 4, Figure 1B), was detected along the different stages of mouse 
embryonic cranio-facial development. Other amelogenin isoforms might also be 
present. We are currently looking for such isoforms. 
 
Spatio-Temporal expression of amelogenin in the cranio-facial complex during 
E10.5-E18.5 mouse embryonic development (Figure 2) 
Amelogenin expression (red – brown staining) was detected in different 
tissues of the mouse embryonic craniofacial complex, at different stages of 
development. No staining was observed in the corresponding control (PBS) sections 
(not shown).  
   
• Amelogenin expression in the developing eye (Figure 2a) 
At E10.5 positive staining for amelogenin was detected at the outer peripheral 
area of the inner part of the optic cup (OC), which gives rise to the photoreceptors. At 
E11.5 staining in the area of the photoreceptors (Pr) facing the future pigment 
epithelium region, was more intense. At E12.5, faint staining was also detected in 
fibers at the inner side of the optic nerve, with the precursors of the photoreceptors 
(Pr) being more intensely stained. Cells at the periphery of the lens stained positively, 
as well as the lens fibers. In the epithelium that will develop into the cornea few cells 
were positively stained (Cr). At E13.5, the fibers, connective tissue and choroidal 
blood vessels (Ch) were positively stained, while still few cells in the cornea (Cr) 
were stained. At E14.5 lens fibers (LF) were positively stained, and faint staining was 
detected in most of the cornea (Cr) cells, as well as in the sclera (Sc). Staining was 
also observed in the vitreous (Vi) but not in the retina (Re), as the photoreceptors 
loose their staining. At E15.5 the lining epithelium at the anterior part of the lens, as 
well as the retina (Re), did not stain, while the choroidal blood vessels stained 
positively (Ch). At E16.5 mainly lens fibers (LF) and the entire choroid (Ch) was 
positively stained. In the ganglion layer (GC) of the retina (Re), cell bodies 
(cytoplasm) and fibers were stained, but at that stage the bipolar cell layer, the 
photoreceptors and the pigment epithelium did not stain with amelogenin antibodies. 
At E18.5 the lens (LF) was completely stained. The retinal vessels and the sub-
epithelial areas (EI) over the eyelids were also stained   
 
• Amelogenin expression in the developing brain (Figure 2a) 
At E10.5 positive staining for amelogenin was detected in the cranial part of 
the neural tube at the external limiting membrane (ELM), where glial cells were 
stained. When fibers were detected – they apparently also stained for amelogenin. 
Most of the staining in the nerve fibers was probably associated with the glial cells, 
however, it is not clear if some axons or dendrites were also stained. At E11.5 
amelogenin expression was detected in the anterior (ventral) regions of the midbrain 
(MB), mainly in fiber-like structures and glial cells. Staining was also observed in the 
tissue that will eventually develop into cartilage at the base of the skull. At E12.5 
positive, but weak, amelogenin staining was detected in the medial part (that is rich in 
fibers) of the telencephalon (Tc), while no staining was detected in the cortical plate 
(CP), which, at that stage comprised mainly of neuroblasts. In general, amelogenin 
staining was observed in both brain hemispheres in fiber-like structures. In most 
cases, the glial cells stained positively, but other cell types (neurons) might also be 
involved. At E13.5, fibers (white material under the cortical plate) stained positively 
while no staining was detected in the cortical neurons. At E14.5 dispersed positive 
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staining of glial cells throughout the brain especially in the midbrain (MB) and pons 
(P), and not only in fiber-like structures, was detected.  At E15.5, staining of nerve 
fibers in the mid-brain (MB) was less prominent, but faint staining in the cerebral 
cortex (CP) was now demonstrated. At E16.5 and E18.5, staining was detected 
throughout the brain except for a thin layer of cortical neurons and around the lateral 
ventricle that was negative (LV). Stronger staining was detected at regions rich in 
fibers or where neurons were not dense; this staining was detected in glial cells. 
However it is unclear if neurons, axons and dendrites were also stained.   
 
• Amelogenin expression in the developing peripheral nerve tracts and fibers 
(Figure 2a) 
At E10.5 almost no nerve fibers were detected. At E11.5 - E16.5 amelogenin 
expression was detected in the developing peripheral nerve (NF), most probably in the 
glial cells. It is unclear if axons and/or dendrites were also stained.  
 
• Amelogenin expression in the developing ganglia and cervical spinal cord 
(Figure 2b) 
At E10.5 the neural tube was not stained for amelogenin. At E11.5 amelogenin 
expression was not detected in the trigeminal ganglion, or in the spinal cord. At E12.5 
amelogenin staining was observed in fiber-like structures in the ventral part of the 
spinal cord. In sites of the spinal cord where vertebrae were more organized – less 
amelogenin staining was detected. At E13.5 positive staining was detected in dorsal 
spinal cord ganglia, however, it is not yet clear which type of cells were stained. At 
E14.5 the entire spinal cord stained positively for amelogenin; the staining was further 
intensified at E15.5. From E14.5 and thereafter up to E18.5 the trigeminal ganglion 
and ganglia at the vicinity of the tooth germ stained positively.  
 
• Amelogenin expression in the developing tooth germ (Figure 2b) 
At E13.5 cells in the dental lamina (DL) were positively stained. At E14.5, in 
the tooth germ (TG), specifically in the region of the stellate reticulum (SR) faint 
positive staining was also detected. At E15.5 staining was still detected in the dental 
lamina (DL), and was also detected in the inner enamel epithelium (IEE). At E16.5, 
staining was observed in the inner enamel epithelium (IEE) and stratum intermedium 
(SI). Faint staining was detected in the stellate reticulum (SR) and almost no staining 
– in the outer enamel epithelium (OEE). The oral epithelium was also stained (not 
shown) while the cervical loop (CL) was faintly stained. Amelogenin staining was 
also detected in developing alveolar bone trabeculae (Av). At E18.5 the dental papilla 
(DP), odontoblasts (Od) and pre-dentin (PD) were slightly stained, the dentin (D) did 
not seem to be stained, followed by very strong purple brown staining of the 
developing extracellular enamel matrix (EM). The ameloblasts (Ab) were stained, but 
not at the outmost region of the ameloblast's cell nucleus. The stratum intermedium 
(SI) and stellate reticulum (SR) surrounding the ameloblasts were only slightly 
stained. These layers are covered by the outer enamel epithelium, which was also 
positively stained. 
 
• Amelogenin expression in the developing cartilage (Figure 2b) 
At E11.5, before cartilage was detected, amelogenin staining was observed in 
the tissue that will eventually develop into cartilage (Pc- prechondrocytes) at the base 
of the skull. At E12.5 some staining was detected in the developing cartilage, mainly 
in surrounding blood vessels but also in some chondrocytes. At E13.5 the cartilage of 
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the vertebrae alongside the cervical spinal cord stained positively. The chondrocytes 
that were not fully differentiated did not stain, while differentiated chondrocytes (DC) 
that underwent hypertrophy stained positively for amelogenin. At E14.5, 
prehypertrophic and hypertrophic chondrocytes (WDC) and the cartilage beneath the 
perichondrium stained positively. This was also observed at E15.5 and E16.5, as 
hypertrophic cartilage (HC) and perichondrium, as well as blood vessels in various 
cranio-facial regions stained positively for amelogenin. At E18.5 both chondrocytes 
and blood vessels in the hypertrophic cartilage stained positively. 
 
• Amelogenin expression in the developing bone (Figure 2b) 
Bone in the craniofacial region was first detected at E13.5.  At that 
developmental stage periosteal osteoblasts, at the beginning of bone organization, 
stained positively. At E14.5, most cell types and not just osteoblasts in the cranial 
bones (mainly membranous bone which does not develop from cartilage), were 
positively stained. The mandibular alveolar bone, which is composed of periosteal 
bone, stained positively at E14.5 and E15.5. However, only faint staining was 
detected in the endochondral mandibular condyle. At E16.5, both endochondral and 
membranous bones in the mandible, maxilla, and their surrounding periosteum, 
stained for amelogenin. This positive staining was also observed at E18.5.  
 
• Amelogenin expression in additional developing tissues (not shown)  
From E10.5 through E18.5 the mesenchyme and connective tissue was 
positively stained for amelogenin. On E11.5 amelogenin expression was detected in 
loosely packed mesenchymal cells at the base of the skull. Amelogenin staining at 
E11.5 was also detected at the region of both, yet vertical, palatine shelves. The palate 
continued to be positive at least until E15.5. The skin and the connective tissue just 
beneath the skin epithelium (future dermis) did not stain at E11.5-E16.5. Only at 
E18.5 the dermis stained positively for amelogenin, while the epithelium still did not 
stain. At E13.5 the connective tissue surrounding the brain (brain membranes) stained 
positively. At E15.5 amelogenin staining was detected in the salivary glands, which 
apparently disappeared at E18.5.  
 
 
Recruitment of mesenchymal cells by amelogenin in the developing mandible  
Agarose beads containing the recombinant human amelogenin (rHAM+, long 
black arrow) (Taylor et al. 2006), were placed along different regions of the 
mandibular mesenchyme of E13.5 mouse embryos. The experimental beads were on 
one side of the mandible, while the control beads (long white arrow) were on the 
contra-lateral side. The ex-vivo mandible was placed in culture for one day and then 
coronal sections were made. Mesenchymal cells apparently moved towards the 
rHAM+ beads and surround the beads (short arrows), while no such cell recruitment 
could be seen around the control PBS agarose bead (Figure 3).  
 
 
Recruitment of mesenchymal cells by amelogenin in the developing incisor tooth 
germ 
Agarose beads containing rHAM+ or PBS (control) were placed on the 
mesenchymal region of the incisor tooth germ of 250µm frontal sections of E14.5 
mandibles. Changes in DiI distribution between 0 and 3 days in culture showed 
movement (recruitment) of mesenchymal cells towards the rHAM+ bead (Figure 4 A-
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D), which eventually partially covered the bead, while no such movement was 
observed towards the control PBS bead (Figure 4 E-H). 
 
 
Discussion 
 
In the present study we focused on the spatio-temporal expression of 
amelogenin in different tissues of the developing embryonic mouse craniofacial 
complex. Our results indicate possible signaling and structural roles for amelogenin 
during early stages of embryonic craniofacial development, in addition to its known 
function during enamel biomineralization. The results clearly show that the 
expression of amelogenin in different tissues is dynamic and depends on the 
embryonic developmental stage. The recruitment of mesenchymal cells in the tooth 
germ and mandible, at early stages of embryonic development, points to the 
functional significance of amelogenin in these tissues.  
 
Many studies in the field of molecular biology and biochemistry, have 
described the function of amelogenin in structural organization and biomineralization 
of enamel; in controlling the size, shape and direction of formation of the enamel 
mineral crystallites ( Fincham et al., 1994; Du et al., 2005). In the past few years, cell 
signaling functions have been attributed to amelogenin low-mass isoforms such as 
LRAP (A-4/M59) ( Nebgen et al., 1999; Veis, 2003; Lacerda-Pinheiro et al., 2006a; 
Lacerda-Pinheiro et al., 2006b;  Zeichner-David et al., 2006; Jegat et al., 2007,). The 
cell surface receptors for amelogenin (M180 and LRAP), were identified, and the 
exact binding regions of amelogenin to its receptors was deciphered (Shapiro et al., 
2007; Zou et al., 2007). We have recently shown that recombinant human amelogenin 
(equivalent to M180) brought about regeneration of the tooth supporting 
mesenchymal tissues: cementum, periodontal ligament and alveolar bone in the dog 
model. This regeneration process involved recruitment of mesenchymal stem cells, 
also indicating signaling role(s) for amelogenin (Haze. et al. in submission). All these 
studies were performed on postnatal tissues. Very few detailed studies were carried 
out on amelogenin expression in the cranio-facial complex during prenatal 
development, and these studies focused mainly on the late stages of prenatal 
development when ameloblasts and odontoblasts had already differentiated, and 
begun to produce developing enamel and the underlying dentin ( Zeichner-David et 
al., 1997; Lacerda-Pinheiro et al., 2006b). This is in contrast to the vast information in 
the literature on other genes, their corresponding proteins and the pathways associated 
with embryonic cranio-facial and specifically with tooth development, morphogenesis 
and differentiation ( Tucker and Sharpe, 1999; Jernvall and Thesleff, 2000; Tucker 
and Sharpe, 2004; Mitsiadis and Smith, 2006).  
  
In the present study we showed that amelogenin mRNA (Figure 1) and protein 
(Figure 2) are expressed in the craniofacial complex from early stages of development 
(E10.5). Amelogenin protein is expressed in some tissues of the cranio-facial complex 
long before the initiation of tooth formation. The amelogenin protein was mainly 
identified in glial cells, in neural-crest derived cells and possibly (but it is still not 
clear yet) in neurons, as it was detected in the brain, the retina of the eye, peripheral 
ganglia and the peripheral nerve trunks. In the craniofacial complex, neural crest cells 
also give rise to non-neuronal ecto-mesenchymal tissues such as bone, cartilage and 
mesenchymal regions of the teeth (Le Douarin et al., 2007) that were all positive for 
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amelogenin. Interestingly, the strongest staining for amelogenin was detected in the 
ameloblasts, extracellular enamel matrix, and the eye lens, that are not thought to be 
neural crest derived. Other epithelial tissues were not intensely stained (cornea), or 
staining was detected at later stages of development (skin, eyelids).  
The expression of amelogenin was studied during mouse embryonic tooth 
germ development, from early stages of development, when the information on the 
spatio-temporal expression of amelogenin is rather scarce, to E18.5, when amelogenin 
expression in the tooth germ (near birth) and postnatally is well documented. 
Amelogenin protein expression was seen already at E13.5 in the dental lamina, and 
continued through embryonic tooth development to E18.5.  From E13.5 up to E16.5 
(E17.5 was not analyzed), no extracellular enamel or dentin are yet formed, and no 
biomineralization of enamel or dentin takes place. Amelogenin, therefore, has 
different function(s) at these stages than that of regulating the size, shape and 
direction of mineral crystal growth. Late in development and close to birth (E18.5), 
amelogenin expression was mainly seen in the mineralizing extracellular enamel 
matrix and in the secreting ameloblasts, and also in the stratum intermedium, pre-
dentin and dentin, and some expression in the dental papilla. The latter expression 
pattern, observed by us at E18.5, has been extensively described, mainly in postnatal 
mice.  
 
A hint on amelogenin function in the early stages of tooth and mandible 
development emerges from the application of amelogenin beads on E13.5 mouse 
embryonic mandibular mesenchyme, which brought about recruitment and cell 
movement towards the beads (Figure 3). This observation was strengthened by the 
application of amelogenin beads, in combination with DiI application, on E13.5 and 
E14.5 embryonic incisor and first molar (not shown) tooth germs mesenchymal tissue, 
respectively. The DiI, which binds to cell membranes, revealed movement of 
mesenchymal cells towards the amelogenin beads, partially covering the beads after 2 
and 3 days (Figure 4). The amelogenin beads contained the recombinant human 
amelogenin protein rHAM+, which is the human amelogenin isoform corresponding 
to the mouse isoform M180 (which contains exons 1-7, lacking exon 4). No such 
recruitment of mesenchymal cells was detected towards the control PBS bead. Since 
amelogenin is endogenously expressed in these mesenchymal and tooth germ tissues 
at the days rHAM+ beads were applied (Figure 2), these experiments represent over-
expression and not ectopic expression. The observed cell recruitment suggests a 
signaling function for amelogenin. This is in line with the accumulating data on the 
signaling function of amelogenin, including our recent data (Haze et al. in 
submission). Other studies in which low molecular mass amelogenin isoforms 
produced ectopically chondrogenic and osteogenic-like tissue and caused ameloblasts 
and odontoblasts differentiation suggested prenatal and postnatal signaling effects for 
the different amelogenin isoforms ( Nebgen et al., 1999; Veis, 2003; Lacerda-Pinheiro 
et al., 2006a; Lacerda-Pinheiro et al., 2006b; Jegat et al., 2007,) (also see introduction 
on possible signaling activity of amelogenin). 
 
As was previously described, amelogenin, which is a structural protein during 
enamel bio-mineralization, regulates the shape, size and direction of mineral crystal 
growth. The patterns of amelogenin expression in lens fibers, in brain fibers and in 
nerve trunk fibers suggest a possible role for amelogenin in elongating structures 
within some developing cells. It is tempting to speculate that the model of elongated 
amelogenin nanospheres (Du et al., 2005) might be somehow relevant to its role in 
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developing fibers, but other mechanisms are also feasible. In the eye, amelogenin is 
mainly expressed in the posterior lens epithelium cells which elongate up to several 
hundred times during the process of differentiation into fiber cells. In the nervous 
tissues; brain, optic nerve and nerve trunks, amelogenin expression was mostly 
localized to fiber like structures. Glial and mesenchymal cells are known to surround 
nerve fibers, whether they are axons or dendrites. Several lines of evidence indicate 
that amelogenin is mainly expressed by the glial cells; (i) virtually no staining for 
amelogenin was detected in the cortex, which is mainly composed of neuroblasts, 
while the sub-cortical regions, where many more glial cells exist, was positively 
stained for amelogenin. (ii) Amelogenin was detected in postnatal glial cells 
surrounding brain neurons but not in the neurons themselves (Deutsch et al., 2006). A 
major role of glial cells during development is to support and direct the growth and 
elongation of neurons.  
 
In 2001, the phenotype of the amelogenin knock out (null) mouse was 
published. The only phenotype described at that time was of abnormal enamel 
formation; the teeth of the amelogenin null mouse expressed a hypoplastic enamel 
phenotype with reduced enamel thickness (Gibson et al., 2001). As often happens, 
additional, different phenotypes of the amelogenin null mouse were later described. A 
progressive deterioration of cementum (a mineralized tissue covering the tooth root 
surface) was observed in the amelogenin null mouse. The defects in cementum were 
characterized by increased presence of osteoclasts, and were also associated with an 
increased expression of receptor activator of nuclear factor-κB ligand (RANKL) near 
the cementum, suggesting that amelogenin may play a role in osteoclastogenesis 
through the RANKL/RANK mediated pathway (Hatakeyama et al., 2003). In 2006, 
an additional phenotypic defect was published: the weight of the null mouse was 
significantly reduced compared to the wild type (Li et al., 2006). No reports have 
been made on phenotypes in other cranio-facial tissues and body organs. This is not 
surprising, since only at 2006 amelogenin expression in other mesenchymal 
mineralizing tissues, such as alveolar bone, long bone and cartilage, and in cranio-facial 
soft tissues such as brain and salivary gland were published (Deutsch et al., 2006; 
Haze et al., 2007). Our recent findings of amelogenin expression in active alveolar bone 
regions (Haze et al. in submission), in epiphyseal growth plate of long bone, its 
expression in osteoblasts, osteoclasts and osteocytes, as well as the periosteum 
suggest that amelogenin is active in bone formation and remodeling (Haze et al., 2007). 
Indeed, as was described above, we found that the recombinant amelogenin brought 
about regeneration of the tooth supporting tissues via recruitment of mesenchymal 
stem cells (Haze et al. in submission). In the present study it is evident that the 
expression of amelogenin in different cranio-facial tissues is dynamic and depends on 
embryonic stage. Our results suggest that additional phenotypes might be revealed 
when cranio-facial and body tissues in which amelogenin was found to be expressed in 
the wild type, will be studied in the null mouse. However, it is possible that different 
compensation pathways lead to normal phenotype in other tissues of the knockout 
mice.   
 
The present study suggests that amelogenin could have structural and 
signaling roles in the development of various tissues of the cranio-facial complex 
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including the developing tooth germ, and also in other body organs. The results of the 
present study open new horizons as to the function(s) of amelogenin in different 
tissues during embryonic cranio-facial development. Naturally, there are numerous 
questions that can be asked and many studies that can be conducted to reveal the 
molecular mechanisms and pathways with which amelogenin is associated.  
 
 
Materials and Methods 
 
Animals  
Embryos from CD-1 mice aged E10.5-E18.5, were used in the present study. 
Embryos from 6 pregnant mice were used for each age. All experiments were 
approved by the Animal Care Ethical Committee of the Faculty of Medicine, The 
Hebrew University of Jerusalem. 
 
Preparation of Embryonic tissues 
Pregnant mice were sacrificed, the embryos were immediately collected, and 
the heads were removed for further analyses. For histology and 
immunohisochemistry, the heads were immediately fixed in 4% Para-Formaldehyde 
(PFA) over-night at 4OC. The tissues were then washed several times in PBS, and 
dehydrated in increasing ethanol concentrations of 30%, 50%, 70%, 80%, 85%, 90%, 
95%, and 100%. The tissues were then immersed in Histoclear / Xylene, embedded in 
paraffin and frontally sectioned (5µm) from the nose in an anterior-posterior direction. 
For mRNA and protein analysis heads were immediately immersed in TRI-
REAGENT (MRC, Cincinnati, OH).  
 
RNA isolation and RT-PCR 
Total RNA was extracted by homogenizing the craniofacial complexes of 
E10.5-E17.5 in TRI-REAGENT (MRC, Cincinnati, OH). RNA isolation was 
performed using the TRI-REAGENT standard protocol. All total RNA extracts were 
subjected to DNase treatment (DNA free, Ambion, Austin, TX) to eliminate any 
possible DNA contamination. Total RNA concentration was determined using the 
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). 
Total RNA was subjected to reverse transcription according to the manufacturer's 
protocol (Superscript RNase H- Reverse Transcriptase kit, Invitrogene, Carlsbad, 
CA). RT and PCR amplification were performed using primers designed according to 
the mouse amelogenin sequence (Gibson et al, 2003), Forward, DD391: 5'-AGA AAC 
TCA CTG AGC ATA CAC-3', and reverse, DD390, 5'-GAT GGA GGG ATG TTT 
GGC TG-3'. PCR products were extracted from 2% agarose gels using Qiaquick gel 
extraction kit (Qiagen, Valencia, CA) and sequenced at the Center for Genomic 
Technologies, Hebrew University (Jerusalem, Israel). 
 
Indirect Immunohistochemistry: 
Slides were deparaffinized, hydrated, rinsed in PBS and endogenous peroxidase 
activity was blocked by 3% H2O2 (diluted in methanol) for 10 min. Slides were blocked 
in non-immune goat serum for 20 min (Histostain-SP kit, Zymed laboratories Inc., San 
Francisco, USA), followed by over-night incubation of the primary antibody (diluted in 
PBS) at 4˚C in a humidified chamber. The first antibodies used were: (a) 270- 
Polyclonal rabbit antibody, raised against amelogenin N-terminus (MPLPPHPG) 
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(identical in mouse, human etc.) and diluted in PBS to 1/500-1/1000. (b) 859 polyclonal 
rabbit antibody raised against rat amelogenin. The specificity of the antibodies was 
previously determined (Haze et al. in submission), by subjecting the antibodies to 
sections obtained from the amelogenin knockout mouse (Gibson et al., 2001) mandible.  
No staining for amelogenin was obtained in the mandible, including, amongst others, 
the ameloblasts and enamel. On the other hand, using the same conditions, some of the 
corresponding wild type tissues, including the ameloblasts and enamel showed strong 
staining for amelogenin.  
After rinsing, slides were treated according to the Histostain-SP kit protocol 
(Zymed laboratories inc., San Francisco, USA). Negative controls included PBS in 
place of the first antibody. For better viewing of the histology of the tissue, the slides 
were stained with hematoxylin (Pioneer Research Chemicals, USA, blue staining). All 
slides were examined by Axioskop (Zeiss, Göttingen, Germany).  The pictures were 
taken using Coolpix 990 digital camera (Nikon, Tokyo, Japan), and ProgRes C10 
(Jenoptik, Jena, Germany). 
 
 
Preparation and culturing of mouse embryonic mandibles 
Freshly harvested (13.5 day) embryo heads were placed in Dulbeco's modified 
Eagle's medium (DMEM) (with L-glutamatmine), containing 20 units/ml 
penicillin/streptomycin (Beit Ha'emek, Israel;Sigma). The mandibles were dissected 
from the cranio-facial complex by using watchmaker's forceps (FST, Vancouver, 
Canada) and 27-gauge sterile needles (Sherwood Medical Industries, Athy, Ireland). 
The dissected mandibles were then placed on a 0.1-µm Millipore filter (Millipore, 
USA) coated with Matrigel (BD Biosciences, USA), and then covered with Matrigel. 
The filter paper with the mandible was then placed on a 35mm triangle stainless steel 
metal grid, with 0.25mm diameter mesh wire (Goodfellows), placed in Falcon 60mm 
Center-well Organ Culture dishes (Becton Dickinson). The center well was filled with 
DMEM (with L-glutamatmine) and 20 u/ml penicillin/streptomycin, up to the 
mesh surface, and the narrow well, surrounding the center well, was filled with double 
distilled sterile water. The cultures were grown in a standard incubator at 37°C with 
an atmosphere of 5% CO2. After incubation in culture for one day, explants were 
washed in ice-cold methanol for 2 min and then fixed in 4% paraformaldehyde for 2h 
at room temperature. The explants were then embedded in paraffin, sectioned, and 
counterstained with eosin for histology. 
 
Bead preparation and placement on mouse embryonic mandible explant cultures 
Affi-gel agarose beads (Biorad) (75-100µm) were separated by size under 
stereomicroscope, washed thoroughly in PBS, air dried, and suspended in rHAM+ 
(Taylor et al. 2006) (1 µg/µl) dissolved in 0.05M acetic acid solution, at 37°C for 30 
min. Prior to use, beads were washed in PBS (neutralizing the acid), and the beads 
were then placed on E13.5  mandibular explant, in the incisor region, the molar 
region, and on the mandible diastema region (experimental beads). Control beads 
were prepared in a similar manner by using only PBS, and were placed on the contra-
lateral side of the mandible in similar regions as the experimental beads. Mouse 
embryonic mandible explant cultures containing Affi-gel beads were grown for one 
day, as described below  
 
Preparation of 250µm thick frontal sections of mouse embryonic mandibles for DiI 
studies 
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E13.5 and E14.5 mouse embryonic mandibles were frontally dissected into 
250µm thick sections, using Mcllwain Tissue Chopper (Science Products GmbH, 
Hofheim, Germany) as described in Matalova et al., 2005. Briefly, sections containing 
first molars, or incisors, were selected under the microscope in medium. Affi-gel 
beads (control and experimental) were placed on the tooth germ mesenchymal region, 
and DiI (Molecular probes, USA) was injected into the mesenchymal cells in the 
vicinity of the beads using a mouth pipette. Slices were placed on a 0.4-µm FalconTM 
cell culture inserts (Falcon, USA). The sliced tissue was then covered with Matrigel 
(BD Biosciences, USA)., and cultured as was described above for the mandibular 
explant for up to 3 days. The cultures were photographed every 24 hours using a 
Leica dissecting microscope under either bright field, dark field or both (for 
superimposition) to monitor the DiI at 0, 1 and 2 days. Cultures were fixed at day 2 
and embedded in wax for sectioning. After sectioning the localization of DiI was 
photographed using a Zeiss Fluorescence compound microscope. Sections were then 
stained for histology and re-photographed. The DiI label is fixable but lost after 
staining for histology. 
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Figure legends: 
 
Fig. 1. (A) Expression of amelogenin cDNA isoform M180 in the mouse 
embryonic cranio-facial complex at E10.5 through E17.5. (B) Schematic 
representation of the exon structure of M180. 
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Fig. 2. Spatio-temporal distribution of amelogenin expression in tissues of E10.5 
to E18.5 mouse embryonic cranio-facial complex (Amelogenin expression - brown-
red staining, hematoxylin – blue staining). (A) In the eye, brain and peripheral nerve 
trunk at E10.5, E11.5, E12.5, E13.5, E14.5, E15.5, E16.5 and E18.5. (B) In the tooth 
germ, cartilage, bone and ganglion at E12.5, E13.5, E14.5, E15.5, E16.5 and E18.5.  
Eye: Ch- choroidal blood vessels; Cr- cornea; EI- sub-epithelial region; GC- ganglion 
layer; LF- lens fibers; OC- optic cup; Pr- photoreceptors; Re- retina; Sc- sclera; Vi- 
vitreous. Brain: C- cortex; CP- cortical plate; ELM- external limiting membrane; LV- 
lateral ventricle; MB- midbrain; P- pons; Tc- telencephalon; TCr- temporal cortex      
TL- temporal lobe. Peripheral nerve trunk: NF- peripheral nerve fibers. Tooth germ: 
Ab- ameloblasts; Av- alveolar bone trabecules; CL- cervical loop; D- dentin; DL- 
dental lamina; DP- dental papilla; EM- extracellular enamel matrix; IEE- inner 
enamel epithelium; Od- odontoblasts; OEE- outer enamel epithelium; PD- pre-dentin; 
SI- stratum intermedium; SR- stellate reticulum; TG- tooth germ. Cartilage: DC- 
differentiated chondrocytes; HC – Hypertrophic cartilage; Pc- Pre-chondrocytes; 
WDC – well developed chondrocytes. Bone: BT – bone trabecules. No amelogenin 
staining was detected in the corresponding control (PBS) sections (not shown). 
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Fig. 3. Possible recruitment of mesenchymal cells in the developing mandible by 
amelogenin (rHAM+) beads but not by control PBS beads. (A, B) rHAM+ beads 
(long black arrow) one days after bead application on E13.5 mouse embryonic 
mandibles. Note the ring of cells surrounding the rHAM+ beads (short arrows). (C) 
PBS bead (long white arrow). No such phenomenon is detected around the control 
bead. 
 
Fig 4. Movement (recruitment) of DiI – labeled mesenchymal cells in the incisor 
tooth germ region, towards amelogenin (rHAM+) beads but not towards control 
PBS bead. Frontal slices through the incisor region of E14.5 mandibles cultured for 
three days after addition of beads. Oral and incisor epithelium are outlined in white. 
The mesenchyme around the incisor cap stage tooth germs (outlined and marked by *) 
was labeled with DiI (orange). (A-D) rHAM+ bead at day 0 (A), day 1 (B), day 2 (C), 
day 3 (D). (A-C) Merged light/dark field image of cultured slice showing DiI label 
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moving towards and around the rHAM+ bead. (D) Section showing DiI cells 
associated with the rHAM+ bead. (E-H) Similar slice with a PBS (control) bead at day 
0 (A), day 1 (B), day 2 (C), day 3 (D). (E-G) Merged light/dark field image of 
cultured slice showing DiI label remaining distinct from the PBS bead. (H) Section 
showing DiI cells not associated with the PBS bead. 
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